MDP Stock Recent News

Former AdTheorent CEO to lead D/Cipher's evolution as the premier cookie-less ad targeting and buying solution for the open Internet NEW YORK , March 17, 2025 /PRNewswire/ -- Today Dotdash Meredith (DDM), the largest digital and print publisher in America, announced the appointment of Jim Lawson as President of D/Cipher, reporting directly to DDM CEO Neil Vogel, to accelerate the growth and development of its D/Cipher contextual ad-targeting solution across the open web. Jim was a co-founder of AdTheorent, a machine-learning powered DSP (media buying platform) not reliant on individual identifiers, and served as CEO from 2019 to 2024.

NEW YORK--(BUSINESS WIRE)--The New York Times Company (NYSE: NYT) announced today that it will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3, 2025, in San Francisco. Meredith Kopit Levien, president and chief executive officer, will participate in a fireside chat at 1:50 p.m. PT (4:50p.m. ET), which will be accessible via live webcast at investors.nytco.com. An archive of the webcast will be available on the company's website for 90 days. About.

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the "Offering") of 7,500,000 common shares of the Company (the "Common Shares") at a public offering price of $4.00 per Common Share for aggregate gross proceeds to the Company of $30,000,000. The Offering was completed pursuant to an underwriting agreement dated January 28, 2025 between Medexus and Raymond James Ltd.

NOT FOR DISTRIBUTION TO UNITED STATES TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has launched an overnight marketed underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”). The Offering is expected to be completed pursuant to an underwriting agreement (the “Underwriting Agreement”) to be entered into between the Company and Raymond James Ltd.

LONDON--(BUSINESS WIRE)--Audiencerate, an innovative technology company, leader in the development of advanced solutions for digital marketing (MarTech) and online advertising (AdTech) announces that it has signed a partnership agreement with V-Valley, a company of the Esprinet Group focused on the distribution of Advanced Solutions. Thanks to its partnership with Microsoft, Audiencerate is at the forefront of integrating artificial intelligence and cloud computing to optimize marketing and adv.

As mortgage rates continue to fall, Meredith Whitney Advisory Group CEO Meredith Whitney joins Market Domination Overtime to break down the overall state of the housing market (XLRE). "I don't think rates are low enough to really get the market moving.

Medexus Pharmaceuticals Inc Q3 2023 Results Conference Call February 9, 2023 8:00 AM ET Company Participants Victoria Rutherford - Investor Relations Ken d'Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Officer Conference Call Participants Andre Uddin - Research Capital Rahul Sarugaser - Raymond James Prasath Pandurangan - Bloom Burton Tania Armstrong-Whitworth - Canaccord Genuity Julian Hung - Stifel Operator Greetings. Welcome to the Medexus Pharmaceuticals Third Quarter 2023 Earnings Call.

Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2023 Earnings Conference Call November 9, 2022 8:00 AM ET Company Participants Victoria Rutherford - Investor Relations, Adelaide Capital Ken d'Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Officer Conference Call Participants Andre Uddin - Research Capital Justin Keywood - Stifel Rahul Sarugaser - Raymond James Scott Henry - ROTH Capital Partners Prasath Pandurangan - Bloom Burton Operator Good morning, ladies and gentlemen and welcome to the Medexus Pharmaceuticals Second Quarter 2023 Earnings Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Ms.

Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2022 Earnings Conference Call June 23, 2022 8:00 AM ET Company Participants Ken d'Entremont - Chief Executive Officer Marcel Konrad - Chief Financial Officer Victoria Rutherford - Investor Relations, Adelaide Capital Conference Call Participants Andre Uddin - Research Capital Scott Henry - Roth Capital Justin Keywood - Stifel Prasath Pandurangan – Bloom Burton Operator Good morning ladies and gentlemen and welcome to the Medexus Pharmaceuticals fourth quarter 2022 earnings call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.